WO1990005736A2 - Nucleoside analogues - Google Patents
Nucleoside analogues Download PDFInfo
- Publication number
- WO1990005736A2 WO1990005736A2 PCT/GB1989/001401 GB8901401W WO9005736A2 WO 1990005736 A2 WO1990005736 A2 WO 1990005736A2 GB 8901401 W GB8901401 W GB 8901401W WO 9005736 A2 WO9005736 A2 WO 9005736A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ratio
- phosphate
- azidothymidine
- diastereoisomers
- nucleoside analogue
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Definitions
- This invention relates to nucleosides and in particular to nucleoside phosphate triesters and processes for their preparation.
- Nucleoside analogues of general formula (I) are currently of considerable interest for use as therapeutic agents in the treatment of viral infections and in particular acquired immunodeficiency syndrome (AIDS) .
- AIDS acquired immunodeficiency syndrome
- AZT Mitsubishi et al., 1985
- HCV human immunodeficiency virus
- nucleoside analogues have found widespread use in the treatment of a number of viral infections; for example, 9- /3-D-arabinofuranosyladenine (araA) in the treatment of herpes simplex encephalitis and disseminated herpes zoster (North et al.I, 1979).
- HIV HIV was first recognised as a distinct clinical entity in 1981 (Gott Kunststoff , et al., 1981).
- the main target in anti-AIDS treatment has been the causative agent itself, the HIV virion.
- HIV depends on a unique viral enzyme, reverse transcriptase (RT) , to proliferate. This enzyme has long been considered an attractive target for an attack on retroviruses (Smith et al., 1974; Chandra et al., 1977).
- RT reverse transcriptase
- AZT As an inhibitor of HIV in lymphocytes has been studied in detail (Furman et al., 1986) .
- AZT requires conversion to its 5 1 - triphosphate ( arqar et al. , 1984; Cooney et al., 1986).
- the nucleoside is monophosphorylated by a nucleoside kinase enzyme present in the cell. Further kinase enzymes convert the monophosphate to the corresponding triphosphate product, which is the bioactive form.
- the bioactive form efficiently and selectively inhibits the HIV reverse transcriptase and its incorporation into DNA results in termination of DNA synthesis.
- nucleoside analogues suffer from a number of problems in relation to their anti-viral activity.
- the compounds are rapidly deactivated.
- deactivation of nucleosides may occur by cleavage of the glycosidic bond by phosphorylase enzymes.
- Phosphorylases are known to cleave the glycosidic bond in natural nucleosides (Stryer, 1981) . Furthermore, phosphorylases have been specifically implicated in the degradation of nucleoside analogues with therapeutic applications (Birnie et al., 1963; Saffhill et al., 1986).
- the nucleosides may be deactivated by deaminase enzymes.
- Deaminases cause the loss of the amine group from the base portion (B) of the nucleoside.
- adehosine deaminase mediates in the deactivation of araA by converting it to arahypoxanthine (Bryson et al., 1976 and Haskell, 1977).
- potent inhibitors of deaminase enzymes have been sought (Cha, 1976; Schaeffer et al., 1974) .
- nucleoside compounds may be improved in the presence of deaminase inhibitors (Agarwal et al., 1978; Sloan et al., 1977), the inhibitors themselves may have undesirable toxic side effects (North et al.II, 1979).
- deamination resistant compounds have been sought.
- a major substrate requirement of adenosine deaminase is a free 5 1 - hydroxyl group (Bloch et al., 1967).
- Many 5 1 - modified adenosine nucleosides have been prepared and are indeed resistant to adenosine deaminase (Declercq et al., 1977).
- a second problem leading to poor clinical response to the nucleosides results from dependence on nucleoside kinases to effect monophosphorylation of the nucleoside. Poor intracellular phosphorylation may result in a poor clinical response to the nucleoside. In some cases a dependence on the virally-coded kinases is advantageous since it leads to enhanced antiviral selectivity (Furman et al., 1979). However, in most cases it is deleterious. There are now many reports of the absence, low activity or deletion of the kinase leading to a poor clinical response to the nucleoside analogue (Reichard P. et al., 1962; Morse P.A. et al., 1965; and Bapat A.R. et al ; 1983 ) .
- a further problem relating to the clinical use of nucleosides is their poor physical properties, in particular their low solubility in water and poor membrane penetrability.
- the triester compounds (II) show increased stability to deactivation by enzymes such as deaminases and may be expected to possess the desired lipophilicity to facilitate crossing of the cell membrane.
- the compounds require hydrolytic cleavage of -the two 'R'-groups. It is postulated that the disappointing bio-activity of these compounds is a consequence of the cells, inability to effect such a hydrolytic cleavage. This is probably a consequence of the general lack of triesterase activity in cells.
- a first aspect of the present invention provides a nucleoside analogue of the formula:
- R 1 ,R 2 ,R 3 ,R 4 and R 5 are the same or different and are selected from -H, alkyl, aryl, acyl, substituted alkyl, substituted aryl and substituted acyl.
- the base portion may be any organic base; for . example, purine or pyrimidine bases.
- the base is adenine, thymine, guanine or cytosine. Most preferably the base is thymine.
- the phosphate group is an asymmetric chiral centre. Consequently the compound may be a single diastereomer or a mixture of diastereomers with respect to the phosphate chiral centre.
- the biological activity of the individual or mixed diastereomers may be different.
- the compounds of the present invention are single diastereomers. More preferably the compounds of the present invention are the most biologically active diastereomers. For example,
- -X may be selected from either -H or -N 3 .
- X - N 3 .
- the nucloside analogue of the present invention may be particularly useful in the treatment of AIDS.
- nucleoside analogues of the present invention have been shown in .in vitro assays to be excellent inhibitors of HIV proliferation.
- an assay in which the nucleoside analogues of the present invention, suitable host cells, and HIV are incubated together indicates that the IC 50 of the compounds (i.e. concentration of the compound required to produce a 50% reduction in the formation of HIV antigen) is typically between 0.05 and 100 ⁇ M.
- IC 50 of the compounds i.e. concentration of the compound required to produce a 50% reduction in the formation of HIV antigen
- Enhanced inhibition may be observed in an assay in which the compounds and host cells are preincubated prior to addition of HIV.
- nucleoside analogues of the present invention are excellent ij vitro inhibitors of HIV proliferation the nucleoside analogues present low toxicity towards uninfected cells.
- the compounds of the present invention overcome the above-mentioned problems associated with the bioactivity of nucleoside analogues in a number of ways.
- the compounds possess enhanced stability towards deactivation;
- the phosphorylated structure of the compounds leads to a reduced dependence on kinase enzymes to phosphorylate the nucleoside;
- third, the uncharged nature of the compounds enables them to cross the lipophilic cell membranes.
- the nitrogen-phosphorus amide bond is hydrolysed, possibly by protease enzymes.
- the resulting phosphate diester may then be further hydrolysed by, for example, diesterase enzymes, to yield the corresponding monophosphate.
- the monophosphate is then a substrate for transformation by kinase enzymes to the corresponding triphosphate, as shown in Reaction Scheme I.
- the bioactive form of the nucleoside is produced. It is not intended to limit this disclosure to this postulate explaining the surprisingly efficacious nature of the compounds of the present invention.
- -Y may be -OR 3 or -NR 4 R 5 .
- Y -OR 3 .
- R 1 ,R 2 ,R 3 ,R 4 and R 5 are the same or different and are selected from hydrogen, alkyl, aryl, acyl, substituted alkyl, substituted aryl and substituted acyl groups.
- the alkyl, aryl, acyl, substituted alkyl, substituted aryl and substituted acyl groups from which R 1 ,R 2 ,R 3 , R 4 and R 5 may be selected comprise C ⁇ to C 10 alkyl, aryl, acyl, substituted alkyl, substituted aryl and substituted acyl groups.
- the groups may be branched or unbranched.
- R 3 is a substituted alkyl group. More preferably, R 3 is a 2,2,2-trihaloethyl group, a 2,2- dihaloethyl group or a 2-haloethyl group. More preferably, R 3 is a 2,2,2-trichloroethyl group such that the compound of the present invention is a 2,2,2-trichloroethyl phosphate ester. In vitro assays have shown compounds of this type to be particularly effective inhibitors of HIV proliferation.
- nucleoside analogue varies the individual substituents -X,-Y,-Z and -B enables the nucleoside analogue's properties to be tuned to the optimum combination for biological activity.
- modification of the structure may enhance the selectivity of hydrolysis in the infected cell; the substituents may also be chosen to enhance the physical characteristics of the nucleoside analogue, for example to increase the lipophilicity and thereby enhance its transport across the cell membrane or to increase the solubility of the nucleoside analogue.
- R 7 may be selected include amino acids, oligopeptides and polypeptides.
- R 2 and/or R 3 cause large variations in the biological activity of the nucleoside analogue.
- the alkyl, aryl, acyl, substituted alkyl, substituted aryl and substituted acyl groups from which R 6 and R 7 may be selected comprise C ⁇ to C 10 alkyl, aryl, acyl, substituted alkyl, substituted aryl and substituted- acyl groups.
- the groups may be branched or unbranched.
- R ⁇ may be selected from 1 to C 3 alkyl groups. More preferably R 6 is methyl or iso-propyl.
- diastereomers corresponding to D- and L- amino acids, about the ⁇ -carbon atom may exist.
- the nucleoside analogue of the present invention may be single diastereomers or a mixture of diastereomers about the ⁇ -carbon asymmetric centre.
- the nucleoside analogue of the present invention are single diastereomers. More preferably, the nucleoside analogue of the present invention is the most biologically active diastereomer.
- nucleoside analogue of the present invention has the nucleoside analogue of the present invention.
- R 3 Me, Et, Pr, Bu, Hex, 2,2,2-trichloroethyl,
- nucleoside analogue of the present invention is selected from:
- the nucleoside analogue of the present invention is 3 ' -azidothymidine-5 '-(2,2, 2-trichloroethyl methoxyalaninyl) phosphate.
- a second aspect of the present invention provides a process for the preparation of a nucleoside analogue according to the first aspect of the present invention.
- the nucleoside analogue according to the first aspect of the present invention may be prepared according to the scheme outlined in Reaction Scheme II.
- Reaction Scheme II Reaction of the phosphorodichloridate (III) with the amine HNR 1 R 2 yields the aminophosphorochloridate (IV) .
- Reaction of the aminophosphorochloridate (IV) with a nucleoside yields a nucleoside monophosphate triester (VI) of the present invention.
- the phosphorodichloridate (III) may be prepared by conventional means.
- Preparation of the amino phosphorochloridate (IV) may be accomplished by reaction of the phosphordichloridate (III) and an amine (HNR 1 R ) under standard conditions (Van Boom et al., 1975; Michaelis, 1903). For example, by the dropwise addition of the amine (R 1 R 2 NH) to the phosphorodichloridate (III) in ether solution at -40°C followed by warming to ambient temperature.
- Reaction of (IV) and (V) to give (VI) may be performed in pyridine as solvent. However, the reaction is slow. Preferably the reaction is performed in THF in the presence of N-methylimidazole.
- nucleoside (V) and 2 equivalents of aminophosphorochloridate (IV) are stirred together for 16 hours at room temperature in THF solution (5 ml/mmol) in the presence of 4 equivalents of N-methylimidazole.
- the nucleoside monophosphate triester (VI) may be isolated by a conventional extractive work up and chromatographic purification.
- a third aspect of the present invention comprises a chemical compound of the formula
- R2 -CHR 6 C0 2
- R 3 ,R 6 ,R 7 are the same or different and are selected from -H, alkyl, aryl, acyl, substituted alkyl, substituted acyl and substituted aryl groups.
- the alkyl, aryl, subsituted alkyl and substituted aryl groups from which R , R and R 7 may be selected comprise C ⁇ to C 10 alkyl, aryl, substituted alkyl and substituted aryl groups.
- the groups may be branched or unbranched.
- the third aspect of the present invention provides the compounds methylmethoxyvalinyl phosphorochloridate, ethylmethoxyvalinyl phosphorochloridate, propylmethoxyvalinyl phosphorochloridate, buty lme hoxy va 1 i ny 1 phosphorochloridate, hexylmethoxyvalinyl phosphorochloridate, ethylmethoxyalaninyl phosphorochloridate, ethylme hoxyphenylalaninyl phosphorochloridate, ethylmethoxyleucinyl phosphorochloridate, ethylmethoxyisoleuciny1 phosphorochloridate, 2,2,2-trichloroethyl methoxyalaniny1 phosphorochloridate.
- a compound of the third aspect of the present invention may be prepared by reaction of an alkoxy phosphorodichloridate R 3 0P(0)C1 2 with an amino acid ester H 2 NCHR ⁇ C0 2 R 7 , for example, by the dropwise addition of the amino acid ester to the alkoxy phosphorodichloridate in ether solution at -40°C followed by warming to ambient temperature.
- a compound of the third aspect of the present invention may be used in the preparation of a nucleoside analogue of the first aspect of the present invention.
- a fourth aspect of the present invention provides a pharmaceutical composition comprising a nucleoside analogue according to the first aspect of the present invention in association with a pharmaceutically acceptable excipient.
- a fifth aspect of the present invention provides a nucleoside analogue according to the first aspect of the present invention in a form suitable for parenteral or oral administration.
- a sixth aspect of the present invention provides a nucleoside analogue according to the first aspect of the present invention for use as a pharmaceutical.
- a seventh aspect of the present invention provides a process for the preparation of a pharmaceutical composition comprising bringing a nucleoside analogue of the first aspect of the present invention into association with a pharmaceutically acceptable excipient.
- An eighth aspect of the present invention provides a method of treatment comprising the administration, to a human or animal in need of such treatment, of an effective amount of a nucleoside analogue according to the first aspect of the present invention.
- the eighth aspect of the present invention provides a method of treatment of a viral infection. More preferably the viral infection is human immunodeficiency virus.
- a ninth aspect of the present invention provides use of a nucleoside analogue according to the first aspect of the present invention for the manufacture of a medicament for the treatment of a viral infection.
- the viral infection is human immunodeficiency virus.
- a tenth aspect of the present invention provides a pharmaceutically acceptable salt or addition compound of a nucleoside analogue according to the first aspect of the present invention.
- the mixture of diastereomers (UCL 12) was partially separated to give fast and slow running fractions (UCL 19 and UCL - 20 respectively) .
- Partial separation was accomplished by HPLC, employing a Waters system using a 25cm x 4.6mm Partisil 5 silica column, and a mobile phase of 90% ethyl acetate/10% petroleum spirit, with a flow rate of 2.0cm 3 /min. Detection was by UV at 254nm.
- 2,2,2-Trichloroethyl methoxyalaninyl phosphorochloridate (0.37g, 1.12mmol) was added to a solution of AZT (0.10g, 0.37mmol) in anhydrous THF (5ml) containing N- methylimidazole (0.42 ml, 5.24 mmol), and the mixture stirred for 16h at ambient temperature. The solvent was removed under reduced pressure, and the residue dissolved in chloroform (30ml) , and extracted with saturated sodium bicarbonate solution (15ml) , and then with water (2x15ml) . The organic phase was dried over magnesium sulphate, and concentrated under reduced pressure.
- Ethyl propylamino phosphorochloridate (0.35g, 1.87mmol) was added to a solution of AZT (0.20g, 0.74mmol) in anhydrous THF (5mL) containing N-methylimidazole (0.30mL, 3.75mmol), and the mixture stirred for 16h at ambient temperature.
- the solvent was removed under reduced pressure, and the residue dissolved in chloroform (30mL) , extracted with saturated sodium bicarbonate solution (15mL) , and then with water (2xl5mL) .
- the organic phase was dried over magnesium sulphate, and concentrated under reduced pressure.
- the residue was precipitated from chloroform (lOmL) , by the addition of petroleum ether (400mL; bp 30-40) .
- TCD50 HTLV III (RF) is added to the total number of cells required (10 7 - 10 8 ) and absorbed to the cells for 90 Min. at 37°C.
- the cells (2xl0 5 /l.5ml) are then cultured in 6 ml tubes with drugs at two concentrations (100 and l ⁇ M) for 72h.
- tissue culture supernatant from each sample is assayed for HIV antigen using a commercial ELISA.
- cells (2x105/1.5ml) are cultured in 6 ml tubes with drugs only at half log dilutions (100 - 0.01 ⁇ M) for 72H.
- the cells are harvested, washed and 14 C incorporation measured .
- the assay results are summarised in Table 1 in which IC 50 ( ⁇ M) for each compound is the micromolar concentration of that compound required to inhibit HIV antigen formation by 50%.
- IC 50 ( ⁇ M) for each compound is the micromolar concentration of that compound required to inhibit HIV antigen formation by 50%.
- the results clearly show that the compounds UCL 11 to UCL 17, UCL 19 to UCL 24 and UCL 89 are effective In vitro inhibitors of HIV, even at concentrations of less than 100 ⁇ M. No assessment of inhibition of HIV antigen formation was performed at concentrations of the compounds above lOO ⁇ l.
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019900701554A KR900701814A (en) | 1988-11-23 | 1989-11-23 | Nucleoside homologue |
DK095791A DK95791A (en) | 1988-11-23 | 1991-05-22 | nucleoside analogues |
FI912489A FI912489A0 (en) | 1988-11-23 | 1991-05-22 | NUKLEOSIDEANALOGER. |
NO91911965A NO911965L (en) | 1988-11-23 | 1991-05-22 | Nucleoside analog. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB8827337.0 | 1988-11-23 | ||
GB888827337A GB8827337D0 (en) | 1988-11-23 | 1988-11-23 | Nucleoside analogues |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1990005736A2 true WO1990005736A2 (en) | 1990-05-31 |
WO1990005736A3 WO1990005736A3 (en) | 1990-07-12 |
Family
ID=10647305
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1989/001401 WO1990005736A2 (en) | 1988-11-23 | 1989-11-23 | Nucleoside analogues |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP0445201A1 (en) |
JP (1) | JPH04502006A (en) |
KR (1) | KR900701814A (en) |
AU (1) | AU626360B2 (en) |
DK (1) | DK95791A (en) |
FI (1) | FI912489A0 (en) |
GB (1) | GB8827337D0 (en) |
WO (1) | WO1990005736A2 (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5614548A (en) * | 1988-10-25 | 1997-03-25 | Wake Forest University | Quaternary amine containing ether or ester lipid derivatives and therapeutic compositions |
US5770584A (en) * | 1993-06-10 | 1998-06-23 | Wake Forest University | Method of treating hepatitis virus infections |
US5962437A (en) * | 1994-08-29 | 1999-10-05 | Wake Forest University | Lipid analogs for treating viral infections |
WO1999049873A1 (en) * | 1998-03-27 | 1999-10-07 | Regents Of The University Of Minnesota | Nucleosides with antiviral and anticancer activity |
US5981507A (en) * | 1995-12-14 | 1999-11-09 | Advanced Magnetics, Inc. | Polymeric carriers linked to nucleotide analogues via a phosphoramide bond |
US7026469B2 (en) | 2000-10-19 | 2006-04-11 | Wake Forest University School Of Medicine | Compositions and methods of double-targeting virus infections and cancer cells |
US7135584B2 (en) | 1995-08-07 | 2006-11-14 | Wake Forest University | Lipid analogs for treating viral infections |
US7309696B2 (en) | 2000-10-19 | 2007-12-18 | Wake Forest University | Compositions and methods for targeting cancer cells |
US7551837B2 (en) | 2001-08-31 | 2009-06-23 | Thomson Licensing | Sequence counter for an audio visual stream |
US8399428B2 (en) | 2004-12-09 | 2013-03-19 | Regents Of The University Of Minnesota | Nucleosides with antiviral and anticancer activity |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3082203A (en) * | 1960-02-10 | 1963-03-19 | American Cyanamid Co | Novel nucleotide coenzymes |
US3280104A (en) * | 1964-04-13 | 1966-10-18 | Syntex Corp | 2', 3'-dideoxyribonucleoside and 2', 3'-dideoxyribonucleotide derivatives |
DE1595938A1 (en) * | 1964-06-12 | 1970-07-09 | Merck & Co Inc | Compounds effective against viruses and processes for their preparation |
US3534017A (en) * | 1967-03-14 | 1970-10-13 | Kyowa Hakko Kogyo Kk | Process for the preparation of nucleoside-5'-diphosphates and triphosphates and mono- and oligo-nucleotidyl-nucleoside-5'-diphosphates and triphosphates |
EP0206497A2 (en) * | 1985-05-15 | 1986-12-30 | The Wellcome Foundation Limited | Therapeutic nucleosides and their preparation |
GB2181128A (en) * | 1985-09-17 | 1987-04-15 | Wellcome Found | 3'-azidonucleosides |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1414252A (en) * | 1921-12-29 | 1922-04-25 | William A Brubaker | Cushion tire |
DE2460051A1 (en) * | 1974-12-19 | 1976-07-01 | Bayer Ag | ONE-PIECE PROTECTIVE TIRES |
DE3101408A1 (en) * | 1981-01-17 | 1982-09-02 | Bayer Ag, 5090 Leverkusen | VEHICLE TIRE |
DE3148313C2 (en) * | 1981-12-07 | 1983-11-03 | Paul Vom Stein & Co, 5632 Wermelskirchen | Roller for apparatus, furniture or the like. |
CA1239854A (en) * | 1984-04-16 | 1988-08-02 | Uniroyal, Inc. | Non-pneumatic tire with supporting and cushioning members |
-
1988
- 1988-11-23 GB GB888827337A patent/GB8827337D0/en active Pending
-
1989
- 1989-11-23 WO PCT/GB1989/001401 patent/WO1990005736A2/en not_active Application Discontinuation
- 1989-11-23 AU AU46542/89A patent/AU626360B2/en not_active Ceased
- 1989-11-23 JP JP2500243A patent/JPH04502006A/en not_active Expired - Lifetime
- 1989-11-23 KR KR1019900701554A patent/KR900701814A/en not_active Application Discontinuation
- 1989-11-23 EP EP90900225A patent/EP0445201A1/en not_active Withdrawn
-
1991
- 1991-05-22 DK DK095791A patent/DK95791A/en unknown
- 1991-05-22 FI FI912489A patent/FI912489A0/en not_active Application Discontinuation
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3082203A (en) * | 1960-02-10 | 1963-03-19 | American Cyanamid Co | Novel nucleotide coenzymes |
US3280104A (en) * | 1964-04-13 | 1966-10-18 | Syntex Corp | 2', 3'-dideoxyribonucleoside and 2', 3'-dideoxyribonucleotide derivatives |
DE1595938A1 (en) * | 1964-06-12 | 1970-07-09 | Merck & Co Inc | Compounds effective against viruses and processes for their preparation |
US3534017A (en) * | 1967-03-14 | 1970-10-13 | Kyowa Hakko Kogyo Kk | Process for the preparation of nucleoside-5'-diphosphates and triphosphates and mono- and oligo-nucleotidyl-nucleoside-5'-diphosphates and triphosphates |
EP0206497A2 (en) * | 1985-05-15 | 1986-12-30 | The Wellcome Foundation Limited | Therapeutic nucleosides and their preparation |
GB2181128A (en) * | 1985-09-17 | 1987-04-15 | Wellcome Found | 3'-azidonucleosides |
Non-Patent Citations (4)
Title |
---|
J. Med. Chem., Vol. 26, 1983 David Farquhar et al.: "Synthesis and Biological Evaluation of Neutral Derivatives of 5-Fluoro-2'-deoxyuridine 5'-Phosphate ", * |
J. Med. Chem., Vol. 27, 1984 Ram R. Chawla et al.: "Bis(m-nitrophenyl) and Bis (p-nitrophenyl) Esters and the Phosphorodiamidate of Thymidine 5'-Phosphate as Potential Sources of Intracellular Thymidine 5'-Phosphate in Mouse Cells i", * |
Patent Abstracts of Japan, Vol 6, No 223, C133, abstract of JP 57-128699, publ 1982-08-10 * |
Patent Abstracts of Japan, Vol 7, No 252, C194, abstract of JP 58-140100, publ 1983-08-19 * |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5614548A (en) * | 1988-10-25 | 1997-03-25 | Wake Forest University | Quaternary amine containing ether or ester lipid derivatives and therapeutic compositions |
US6030960A (en) * | 1993-06-10 | 2000-02-29 | Wake Forest University | Method of treating hepatitis virus infections |
US5770584A (en) * | 1993-06-10 | 1998-06-23 | Wake Forest University | Method of treating hepatitis virus infections |
US7141557B2 (en) | 1994-08-29 | 2006-11-28 | Wake Forest University | Lipid analogs for treating viral infections |
US7294621B2 (en) | 1994-08-29 | 2007-11-13 | Wake Forest University | Lipid analogs for combating tumors |
US8106032B2 (en) | 1994-08-29 | 2012-01-31 | Wake Forest University | Lipid analogs for combating tumors |
US7294619B2 (en) | 1994-08-29 | 2007-11-13 | Wake Forest University | Lipid analogs for inhibiting the activity of hepatitis B antigen |
US7294620B2 (en) | 1994-08-29 | 2007-11-13 | Wake Forest University | Lipid analogs for inhibiting HIV-1 activity |
US7129227B1 (en) | 1994-08-29 | 2006-10-31 | Wake Forest University | Lipid analogs for treating viral infections |
US5962437A (en) * | 1994-08-29 | 1999-10-05 | Wake Forest University | Lipid analogs for treating viral infections |
US7135584B2 (en) | 1995-08-07 | 2006-11-14 | Wake Forest University | Lipid analogs for treating viral infections |
US5981507A (en) * | 1995-12-14 | 1999-11-09 | Advanced Magnetics, Inc. | Polymeric carriers linked to nucleotide analogues via a phosphoramide bond |
US6475985B1 (en) | 1998-03-27 | 2002-11-05 | Regents Of The University Of Minnesota | Nucleosides with antiviral and anticancer activity |
WO1999049873A1 (en) * | 1998-03-27 | 1999-10-07 | Regents Of The University Of Minnesota | Nucleosides with antiviral and anticancer activity |
US8138200B2 (en) | 1999-10-28 | 2012-03-20 | Wake Forest University | Compositions and methods for double-targeting virus infections and targeting cancer cells |
US7026469B2 (en) | 2000-10-19 | 2006-04-11 | Wake Forest University School Of Medicine | Compositions and methods of double-targeting virus infections and cancer cells |
US7309696B2 (en) | 2000-10-19 | 2007-12-18 | Wake Forest University | Compositions and methods for targeting cancer cells |
US7551837B2 (en) | 2001-08-31 | 2009-06-23 | Thomson Licensing | Sequence counter for an audio visual stream |
US8399428B2 (en) | 2004-12-09 | 2013-03-19 | Regents Of The University Of Minnesota | Nucleosides with antiviral and anticancer activity |
US8765935B2 (en) | 2004-12-09 | 2014-07-01 | Regents Of The University Of Minnesota | Nucleosides with antiviral and anticancer activity |
US8815830B2 (en) | 2004-12-09 | 2014-08-26 | Regents Of The University Of Minnesota | Nucleosides with antiviral and anticancer activity |
Also Published As
Publication number | Publication date |
---|---|
DK95791D0 (en) | 1991-05-22 |
AU626360B2 (en) | 1992-07-30 |
JPH04502006A (en) | 1992-04-09 |
GB8827337D0 (en) | 1988-12-29 |
FI912489A0 (en) | 1991-05-22 |
DK95791A (en) | 1991-05-22 |
EP0445201A1 (en) | 1991-09-11 |
WO1990005736A3 (en) | 1990-07-12 |
AU4654289A (en) | 1990-06-12 |
KR900701814A (en) | 1990-12-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2012223012B2 (en) | Phosphoramidate derivatives of 5 - fluoro - 2 ' - deoxyuridine for use in the treatment of cancer | |
AU2003217863B9 (en) | Nucleotide mimics and their prodrugs | |
EP0322384B1 (en) | Nucleosides for use in therapy | |
EP0820461B1 (en) | Aryl-ester phosphoramidate derivatives of 2',3'-didehydronucleosides | |
JP3628324B2 (en) | Phosphotriester type biologically active compounds | |
WO2003062256A1 (en) | 2'-beta-modified-6-substituted adenosine analogs and their use as antiviral agents | |
WO2006121820A1 (en) | Phosphoramidate prodrugs for treatment of viral infection | |
EP0352248A1 (en) | Nucleoside derivatives | |
WO2003062255A2 (en) | Sugar modified nucleosides as viral replication inhibitors | |
AU5494501A (en) | Anti-viral pyrimidine nucleoside analogues | |
AU626360B2 (en) | Nucleoside analogues | |
WO1998038202A1 (en) | Antiviral phosphonate prodrugs of nucleosides and nucleoside analogues | |
Harris et al. | Synthesis and antiviral evaluation of phosphoramidate derivatives of (E)-5-(2-bromovinyl)-2′-deoxyuridine | |
Jones et al. | Synthesis and anti-HIV activity of some novel phosphorodiamidate derivatives of 3′-azido-3′-deoxythymidine (AZT) | |
Raju et al. | Synthesis and biological properties of purine and pyrimidine 5'-deoxy-5'-(dihydroxyphosphinyl)-. beta.-D-ribofuranosyl analogs of AMP, GMP, IMP, and CMP | |
McGuigan et al. | Phosphate derivatives of AZT display enhanced selectivity of action against HIV1 by comparison to the parent nucleoside | |
US7217815B2 (en) | 2-beta -modified-6-substituted adenosine analogs and their use as antiviral agents | |
Franchetti et al. | Synthesis and Evaluation of Anti-HIV-1 and Antitumor Activity of 2′, 3′-didehydro-2′, 3′-dideoxy-3-deazaadenosine, 2′, 3′-dideoxy-3-Deazaadenosine and Some 2′, 3′-dideoxy-3-deaza-adenosine 5′-dialkyl Phosphates1 | |
EP0460045A1 (en) | Nucleoside analogues | |
EP2630152B1 (en) | Nucleotide analogue, method of synthesis of nucleotide analogue, use of nucleotide analogue, antiviral pro-nucleotide, pharmaceutical composition | |
McGuigan et al. | Synthesis and Evaluation of 5-Halo 2′, 3′-Didehydro-2′, 3′-Dideoxynucleosides and their Blocked Phosphoramidates as Potential Anti-Human Immunodeficiency virus Agents: An Example of ‘Kinase Bypass’ | |
Hiebl et al. | Side-Chain Derivatives of Biologically Active Nucleosides. Part 2: Synthesis and anti-HIV Activity of 5′-C-Methyl Derivatives of 3′-Fluoro-3′-Deoxythymidine | |
US20040158054A1 (en) | Di-ribonucleotides as specific viral RNA-polymerase inhibitors for the treatment or prevention of viral infections | |
McGuigan et al. | Synthesis and Evaluation of Some Symmetrical Phosphate Dimer Derivatives of 3′-Modified Nucleosides as Potential anti-HIV Agents | |
Abdallah et al. | Application of the protide strategy to some novel nucleoside analogues |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AU BR DK FI JP KR NO SU US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH DE ES FR GB IT LU NL SE |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AU BR DK FI JP KR NO SU US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH DE ES FR GB IT LU NL SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1990900225 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 912489 Country of ref document: FI |
|
WWP | Wipo information: published in national office |
Ref document number: 1990900225 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1990900225 Country of ref document: EP |